Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen G Haggerty

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Immunotoxicology|October 30, 2008
Immunotoxicity testing in non-rodent speciesHelen G Haggerty
The AAPS Journal|February 9, 2018
Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical StudiesDanuta J Herzyk, Helen G Haggerty
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 15, 2012
Chronic administration of belatacept, a T-cell costimulatory signal blocker, in cynomolgus monkeysHelen G Haggerty, Stanley J Proctor
Journal of Immunotoxicology|November 24, 2012
Methods: implementation of in vitro and ex vivo phagocytosis and respiratory burst function assessments in safety testingWendy J Freebern, Tammy J Bigwarfe, Karen D Price, et al.
Journal of Immunotoxicology|October 30, 2008
Meeting Report Immune-Mediated Drug Hypersensitivity Reactions (IDHR) WorkshopThomas T Kawabata, Helen G Haggerty, Amy L Lavin, et al.
Arthritis and Rheumatism|August 1, 2007
Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in miceCarolyn L Bigbee, Daryl G Gonchoroff, George Vratsanos, et al.
Journal of Immunotoxicology|June 11, 2013
Immunomodulation and lymphoma in humansRafael A Ponce, Thomas Gelzleichter, Helen G Haggerty, et al.
The Journal of Rheumatology|December 1, 2007
Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritisHelen G Haggerty, Mark A Abbott, Timothy P Reilly, et al.
Toxicology and Applied Pharmacology|October 18, 2020
Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibodyJoshua T Gamse, Wendy Freebern, Rashade Haynes Ii, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 9, 2021
Thymic Lymphomas in a 6-Month rasH2-Tg Mouse Carcinogenicity Study With the RORγt Inverse Agonist, BMS-986251Helen G Haggerty, Jean G Sathish, Carol R Gleason, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Immunotoxicology|October 30, 2008
Immunotoxicity testing in non-rodent speciesHelen G Haggerty
The AAPS Journal|February 9, 2018
Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical StudiesDanuta J Herzyk, Helen G Haggerty
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 15, 2012
Chronic administration of belatacept, a T-cell costimulatory signal blocker, in cynomolgus monkeysHelen G Haggerty, Stanley J Proctor
Journal of Immunotoxicology|November 24, 2012
Methods: implementation of in vitro and ex vivo phagocytosis and respiratory burst function assessments in safety testingWendy J Freebern, Tammy J Bigwarfe, Karen D Price, et al.
Journal of Immunotoxicology|October 30, 2008
Meeting Report Immune-Mediated Drug Hypersensitivity Reactions (IDHR) WorkshopThomas T Kawabata, Helen G Haggerty, Amy L Lavin, et al.
Arthritis and Rheumatism|August 1, 2007
Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in miceCarolyn L Bigbee, Daryl G Gonchoroff, George Vratsanos, et al.
Journal of Immunotoxicology|June 11, 2013
Immunomodulation and lymphoma in humansRafael A Ponce, Thomas Gelzleichter, Helen G Haggerty, et al.
The Journal of Rheumatology|December 1, 2007
Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritisHelen G Haggerty, Mark A Abbott, Timothy P Reilly, et al.
Toxicology and Applied Pharmacology|October 18, 2020
Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibodyJoshua T Gamse, Wendy Freebern, Rashade Haynes Ii, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 9, 2021
Thymic Lymphomas in a 6-Month rasH2-Tg Mouse Carcinogenicity Study With the RORγt Inverse Agonist, BMS-986251Helen G Haggerty, Jean G Sathish, Carol R Gleason, et al.
Pageof 2